Current process and future path for health economic assessment of pharmaceuticals in France

Figures & data

Fig. 1. Establishment of the CEESP.

Fig. 2. Organisation of the French HTA and pricing system. Dashed arrows indicate the support of the subcommittees/services to the different committees in their work.

Fig. 3. The coordinated assessment/appraisal (8).

Fig. 4. Steps of the early advice meeting.

Fig. 5. Economic appraisal process. Adapted from HAS, Economic appraisal process (8). *Administrative compliance and scientific/methodological compliance. Key actors: 2–3 project managers from the Health Economics and Public Health Department (SEESP) + economics sub-committee rapporteur + possibility to submit questions to external clinical and/or methodological experts. **Key actors: the CEESP members: economic, clinical public health, and social science experts (monthly meeting).

HAS. Production of economic opinion on drugs and medical devices in France: Challenges and issues. 2014; Washington, DC: HTAi.

 Google Scholar